Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 13/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 4/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29970903 | 1.00 | PTPN11 (0.46) | PTPN11MAP4K4KCNH2RETJAK3 | |
| SCHEMBL29970892 | 1.00 | PTPN11 (0.46) | PTPN11MAP4K4KCNH2RETJAK3 | |
| SCHEMBL29969800 | 0.93 | PTPN11 (0.47) | PTPN11MAP4K4KCNH2RET | |
| SCHEMBL23208806 | 0.92 | PTPN11 (0.51) | PTPN11KCNH2 | |
| SCHEMBL23208873 | 0.92 | PTPN11 (0.51) | PTPN11KCNH2 | |
| SCHEMBL23209070 | 0.92 | PTPN11 (0.51) | PTPN11KCNH2 | |
| SCHEMBL29971230 | 0.91 | PTPN11 (0.47) | PTPN11MAP4K4KCNH2JAK3BTK | |
| SCHEMBL29970003 | 0.90 | PTPN11 (0.46) | PTPN11MAP4K4RETJAK3BTK | |
| SCHEMBL23229440 | 0.90 | PTPN11 (0.46) | PTPN11MAP4K4RETJAK3BTK | |
| SCHEMBL23229367 | 0.89 | PTPN11 (0.48) | PTPN11MAP4K4RETJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466016-B2 | Pharmaceutical compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466016-B2 | Pharmaceutical compounds | MAPT, CYP3A5, SLC5A1 | PTPN11 326/4885MAP4K4 782/4885KCNH2 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.